Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Zeiss Introduces Cataract-Only Version of DORC Eva Nexus
German company Carl Zeiss Meditec introduced on Aug. 27 a dedicated cataract version of the DORC Eva Nexus surgical system. The original Eva Nexus, a dual-function cataract and vitrectomy machine, ...
US FDA Accepts NDA for Glaucoma Drop from Nicox and Kowa, Sets PDUFA Date of April 30, 2027
France’s Nicox announced Aug. 27 that the US FDA had accepted the new drug application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911) and set a Prescription Drug User Fee Act (PDUFA) t...
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
Indigo Light Prevents Myopia in Animal Model, Researchers Find
Vision researchers have found that indigo light prevents myopia completely in a tree shrew model. Their findings were published Aug. 18, 2026, in Cell Reports Medicine. The study’s lead researchers...
Light-Filtering Lenses for Migraine from Avulux Gain US FDA De Novo Marketing Nod
Avulux announced Aug. 24 that its eyeglass lenses had gained US FDA de novo marketing authorization to decrease the impact of light sensitivity in patients ages 12 and older diagnosed with episodic...
Santen Launches Rhopressa Glaucoma Drops in Japan
Santen announced Aug. 17 that it had launched Rhopressa (netarsudil ophthalmic solution) 0.02%, an eye drop targeting glaucoma and ocular hypertension, in Japan. The treatment gained marketing appr...
Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt
Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...
Biosimilars, Longer-Acting Treatments Depress Exudative Retinal Pharma Revenue
Total manufacturers’ revenue from pharmaceuticals for exudative retinal diseases are on course to decline for the second year in a row—a first since the introduction of anti-VEGF therapy in 2004. M...
Q2-2026 Ophthalmic Revenue Roundup for STAAR, Lensar, Iridex, and Lenz
STAAR Surgical, of Lake Forest, California, reported Aug. 12 that its Q2-2026 net sales were $93.5 million, a 111 percent increase over $44.3 million in Q2-2025. China sales in Q2-2026 were $52.3 m...
Lupin’s Visufarma Licenses Yuvezzi Presbyopia Drops for Europe, UK
Visufarma, a subsidiary of India-based Lupin Limited, announced Aug. 20 that it had licensed exclusive rights to the presbyopia drop Yuvezzi in the European Union, the UK, Switzerland, Norway, and ...
TearCare Label Expanded to Include Improvement of Meibomian Gland Function
Sight Sciences reported Aug. 19 that the US FDA had expanded the labeling for the TearCare thermal expression device to include improvement of meibomian gland function in adult patients with evapor...
ASRS Meeting Shines Light on Ingenuity of Retina Surgeons Around the Globe
The 2026 annual meeting of the American Society of Retina Specialists (ASRS), held in mid-July at the Palais des Congrès in Montreal, Quebec, opened with a deep dive into surgery. The first day off...
Past News Stories
Quarterly Revenue Roundup for Carl Zeiss Meditec and Santen
German company Carl Zeiss Meditec reported Aug. 6 that its ophthalmic device revenue for the three months ended June 2026 (the third quarter of its fiscal 2025/2026 year) was €437.6 million ($499.7...
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
Zeiss Gains US FDA 510(k) Clearance for Clinic 360 Data Management Software
Carl Zeiss Meditec announced Aug. 19 that it had gained 510(k) clearance from the US FDA for its Clinic 360 image and data management software. The clinical analytics dashboard combines diagnostic ...
Researchers Aim to Conquer Jet Lag Using Engineered RPE Cells
Researchers at Rice and Northwestern universities have developed a subcutaneous therapy using engineered retinal pigment epithelial (RPE) cells that they say could help the body adapt more quickly ...
Ophthalmic Market Poised for Steady Growth Amid Digital Shift, Rising Demand
Ophthalmology continues to expand as global demand for eye care rises, digital technology moves deeper into clinical workflows, and manufacturers push new approaches to diagnosis and treatment. The...
AI Funding Boom Reshapes Venture Capital as Ophthalmology Investment Holds Steady
Record venture capital investment in the first half of 2026 was driven by artificial intelligence (AI) mega-rounds, while ophthalmology continued to draw steady investor interest. AI dominated H1-2...
Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion
Tarsus Pharmaceuticals, maker of Xdemvy drops for Demodex blepharitis, has ventured into the retina sector recently with two acquisitions that could end up topping $1 billion. Tarsus said its deals...
Select US FDA Approvals and Clearances in July 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in July 2026, according to the agency’s database. iHealthscreen received clearance for its iPredi...
PDUFA Dates for Ophthalmic Drug Candidates, August 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
India’s Biocon Launches Aflibercept Biosimilar Yesafili in the US
India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...
Alcon Drops Development of PowerVision Accommodating Lens
Alcon reported Aug. 10 in its Q2-2026 earnings report that it had discontinued work on the PowerVision FluidVision accommodating IOL, following analysis of the latest clinical study data. Alcon sai...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.